Vinita Gupta, 

Gupta is navigating Lupin through turbulent times for the sector in India. Under her leadership, Lupin has built a strong position in the specialty business in the U.S. and Europe with drugs focussing on women’s health, neurology, and movement disorders. But due to the challenging environment, Lupin’s profitability took a hit in FY19. The green shoots of recovery are visible in FY20, with Lupin—the third largest Indian pharma company by global sales and eighth largest in the world— reporting a 49.5% year-on-year rise in net profit to ₹303 crore in the June quarter and a 15.4% rise in sales to ₹4,356 crore.